glp-1 gip dual agonist Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Targeting GLP-1, GIP & GCG
Description
2017;66:A315A315315
Douton et al
For most patients, the most effective longterm strategy after achieving a target weight is to continue GLP1 treatment
What kind of warnings are currently on these drug labels
Oral semaglutide has been approved and recently marketed in Spain following evidence from the Phase 3 clinical trial program Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
CagriSema: the most advanced of the next wave Furthest along of all is Novo Nordisks CagriSema, a fixed-dose combination of the amylin analogue cagrilintide and semaglutide given as a single weekly injection
